Бевацизумаб (Авастин®) в терапии опухолей мозга. Обзор литературы

Автор: Щербенко Олег Ильич

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 3 т.12, 2012 года.

Бесплатный доступ

Представлен обзор литературы, посвященный результатам использования Бевацизумаба (Авастина ®) при опухолях головного мозга. Большинство опубликованных работ посвящено применению Бевацизумаба при рецидивах и резистентных формах злокачественных глиом у взрослых, и небольшое число посвящено использованию препарата в таких же ситуациях у детей и при первичном химиолучевом лечении глиом у взрослых. В результате применения Бевацизумаба достигнуто увеличение сроков жизни больных без прогрессирования опухоли, но рост показателей выживаемости получен только при использовании препарата в качестве лечебного комплекса первой линии в сочетании с другими химиопрепаратами и лучевой терапией. Бевацизумаб проявил способность уменьшать перитуморальный отек, снижая потребность в применении кортикостероидов. Осложнения в виде тромбофлебитов, кровоизлияний, артериальной гипертензии, замедленного заживления ран и миелодепрессии наблюдаются сравнительно редко и, как правило, не носят фатального характера. Полученные данные свидетельствуют о целесообразности дальнейших исследований с применением Бевацизумаба при химиолучевом послеоперационном лечении первичных больных злокачественными глиомами.

Еще

Дети, опухоли мозга, бевацизумаб (авастин), bevaсizumab (avastin®)

Короткий адрес: https://sciup.org/14955340

IDR: 14955340

Список литературы Бевацизумаб (Авастин®) в терапии опухолей мозга. Обзор литературы

Von Baumgarten L, Brucker D, Tirniceru A, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.//Clin Cancer Res. 2011. V.17. N19. P.6192-6205.
Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.//Ann Oncol. 2008. V.19 N4. P. 807-808.
Burkhardt JK, Riina H, Shin BJ, et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.//World Neurosurg. 2012. V.77. N1. P.130-134.
Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.//Adv Ther. 2011. V.28. N4. P.334-340.
Couec ML, André N, Thebaud E, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.//Pediatr Blood Cancer. 2012. V. 57. N1. P.17-21.
Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012. V.82 N5. P.2018-2024.
Desjardins A, Reardon DA, Coan A. et al. Bevacizumab and daily temozolomide for recurrent glioblastoma.//Cancer. 2012. V.118. N5. P.1302-1312.
Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain.//Int J Radiat Oncol Biol Phys. 2007. V. 67. N2. P.323-326.
Grabner G, Nöbauer I, Elandt K, et al. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.//Magn Reson Imaging. 2012. V.30 N.1. P.139-147.
Gronier S, Bourg V, Frenay M, et al. Bevacizumab for the treatment of cerebral radionecrosis.//Adv Ther. 2011. V.28. N4. P. 334-340.
Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study.//J Neurooncol. 2008. V.89. N1. P.113-118.
Guillamo JS, Anti-angiogenic strategies in glioblastoma.//Rev Neurol (Paris). 2011. V.167. N10. P.662-667.
Hofer S, Elandt K, Greil R, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.//Acta Oncol. 2011. V.50. N5. P.630-635.
Jakobsen JN, Hasselbalch B, Stockhausen MTat al. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.// Expert Opin Pharmacother. 2011.V.12. N5. P.825-833.
Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.//J Neurooncol. 2008. V.89 N1 P.113-118.
Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.//Neuro Oncol. 2011. V.13. N10. P.:1143-1150.
Kuczynski EA, Patten SG, Coomber BL. VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human glioma.//Oncology. 2011. V.81. N2 P.126-134.
Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.//Int J Radiat Oncol Biol Phys. 2009.V. 75 N4. P.1148-1154.
MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents.//J.Neuro Oncol. 2011. V. 13 N10. P.1049-1058.
Matuschek C, Bölke E, Nawatny J, et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis.// Strahlenther Onkol. 2011. V.187. N2. P.135-139.
Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.// J Neurosurg. 2012. V.116. N 2. P.341-345.
Narayana A, Kunnakkat S, Chacko-Mathew J, et.al. Bevacizumab in recurrent high-grade pediatric gliomas.//Neuro Oncol. 2010. V. 12. N9. P. 985-990.
Narayana A, Kunnakkat SD, Medabalmi P, et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.//Int J Radiat Oncol Biol Phys. 2012.V. 82. N.1. P.77-82
Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.//J Neurooncol. 2012. V.106. N1. P.121-125.
Parekh C, Jubran R, Erdreich-Epstein, et al.Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.//J Neurooncol. 2011. V.103. N3. P.673-680.
Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma.//Cancer Manag Res. 2010. V. 22. N2. P. 97-104.
Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.//Pediatr Blood Cancer. 2011. V.56. N12. P.230-234.
Pu JK, Chan RT, Ng GK, et al. Using bevacizumab in the fight against malignant glioma: first results in Asian patients.//Hong Kong Med J. 2011 V.17. N4. P.274-279.
Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.//J Neurooncol. 2012. V.107. N1. P.155-164.
Reismüller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors.//Pediatr Blood Cancer. 2010 V. 54. N5. P. 681-686.
Seet RC, Rabinstein AA, Lindell PE, et al. Cerebrovascular events after bevacizumab treatment: an early and severe complication.//Neurocrit Care. 2011. V.15.N3. P.421-427.
Specenier P. Bevacizumab in glioblastoma multiforme.// Expert Rev Anticancer Ther. 2012. V.12. N1. P.9-18.
Vauleon E, Mesbah H, Gedouin D, et al. Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab.//Bull Cancer. 2012. V.99. N2. P.121-126.
Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.//Oncologist. 2010. V.15. N12. P.1329-1334.
Wolff JE, Brown RE, Buryanek J, et al. Preliminary experience with personalized and targeted therapy for pediatric brain tumors.//Pediatr Blood Cancer. 2011. V.56 N12. P.55-59.
Wolff JE, Rytting ME, Vats TS, et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.//J Neurooncol. 2012 V.106 N2: P.391-397.
Wong ET, Gautam S, Malchow C, et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.//J Natl Compr Canc Netw. 2011. V.9 N4. P.403-407.

Еще

Статья обзорная